Vaccines

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

The Meharry and Vanderbilt-based expert shares insights into reaching less trustful populations on the first podcast episode.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.

The country is split on certain strategies and a potential vaccine. Here's why the message needs to go from national to regional.

Is it still safe to take your child to get a vaccine during the pandemic? According to experts, there are safety measures in place for this critically important task.

J&J is evaluating both 1- and 2-dose regimens of the adenovirus vector investigational vaccine.

What the AstraZeneca vaccine research pause meant for physician-patient discussion on vaccine candidate safety.

What we've seen non-immunized communities do for previously eradicated outbreaks.

The logistics of supplying the vaccine are being handled by a collaboration of federal agencies. The DoD, parts of HHS, and CDC are coordinating supply, production, and distribution.

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.

A new study in The Lancet maps trends in vaccine confidence around the world.

Heat Biologics CEO Jeff Wolf talks with Contagion about the firm's effort to develop a vaccine for the coronavirus which can potentially be administered for some seniors by taking advantage of prior immune mechanisms.

One effort to develop a SARS-CoV-2 vaccine focuses on combining antibody and T cell immunity, using a gp96 protein based technology.

Walter A. Orenstein, MD, answers audience questions collected during our Vaccine Race webinar.

David Ho, MD, shares insight into the public and scientific health shortcomings which burdened the nation back in March.

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

Manufacturers announce their supplies are being sent out for the upcoming season.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.